Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Biliary Tract Cancers
NCT04645160Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of tivozanib in biliary tract cancer (BTC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate at 8 weeks and Recommended Phase II Dose at 8 weeks. Started Mar 2022; status: recruiting.
02
Drugs
tivozanib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04645160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645160.